#1 Clinical Trials Search in Europe

Ondansetron

This article examines the use of Ondansetron, a medication commonly used to prevent nausea and vomiting, in various clinical trials. These studies primarily focus on comparing different formulations of Ondansetron, including tablets, orally disintegrating tablets (ODT), and orally dissolving film strips (ODFS), to assess their bioequivalence and effectiveness under different conditions. The trials aim to provide valuable insights into the drug’s performance and its potential benefits for patients.

Table of Contents

What is Ondansetron?

Ondansetron is a medication primarily used to prevent nausea and vomiting. It belongs to a class of drugs called serotonin 5-HT3 receptor antagonists[1]. This medication is also known by its brand name Zofran, which is manufactured by GlaxoSmithKline[2].

Uses of Ondansetron

Ondansetron is prescribed for several conditions that cause nausea and vomiting:

  • Postoperative Nausea and Vomiting (PONV): This is a common side effect after surgery, especially following procedures like vitrectomy (eye surgery) or thyroidectomy (thyroid gland removal)[1][3].
  • Chemotherapy-Induced Nausea and Vomiting: Ondansetron helps cancer patients manage nausea and vomiting caused by chemotherapy treatments[4].
  • Nausea and Vomiting in Pregnancy: Although not explicitly mentioned in the trials, Ondansetron is sometimes used to treat severe morning sickness in pregnant women.
  • Prevention of Hypotension During Spinal Anesthesia: In some cases, Ondansetron is used to help prevent low blood pressure during spinal anesthesia for cesarean sections[5].

How Ondansetron Works

Ondansetron works by blocking the action of serotonin, a natural substance in the body that can trigger nausea and vomiting. Specifically, it inhibits the Bezold-Jarisch reflex, which is responsible for causing hypotension (low blood pressure) and bradycardia (slow heart rate) in response to certain stimuli[5]. By blocking this reflex, Ondansetron can help prevent nausea, vomiting, and in some cases, low blood pressure.

Forms and Administration

Ondansetron comes in several forms:

  • Tablets: Regular tablets that you swallow with water[2].
  • Orally Disintegrating Tablets (ODT): These tablets dissolve in your mouth without needing water[4].
  • Orally Dissolving Film Strip (ODFS): A thin strip that dissolves on your tongue[4].
  • Intravenous (IV) Injection: Given directly into a vein by a healthcare professional[5].

The dosage and form of Ondansetron prescribed will depend on the specific condition being treated and the patient’s individual needs.

Effectiveness

Several studies have shown Ondansetron to be effective in preventing nausea and vomiting:

  • In patients undergoing vitrectomy surgery, Ondansetron combined with dexamethasone (another anti-nausea medication) was found to be effective in preventing PONV[1].
  • For cesarean sections, Ondansetron has shown promise in reducing the amount of other medications needed to maintain blood pressure during spinal anesthesia[5].
  • Studies comparing different forms of Ondansetron (such as orally disintegrating tablets and orally dissolving film strips) have shown them to be equally effective, giving patients more options for taking the medication[4].

Side Effects

While Ondansetron is generally well-tolerated, it can cause some side effects. Common side effects may include:

  • Headache
  • Constipation
  • Dizziness
  • Tiredness

More serious side effects are rare but can include allergic reactions or changes in heart rhythm. It’s important to discuss any side effects with your healthcare provider[1].

Precautions

While Ondansetron is a valuable medication for many patients, there are some precautions to consider:

  • Drug Interactions: Ondansetron may interact with other medications. For example, one study suggested a potential interaction between Ondansetron and acetaminophen (paracetamol) in post-operative pain management[3].
  • Pregnancy and Breastfeeding: While Ondansetron is sometimes used for severe morning sickness, its safety during pregnancy and breastfeeding should be discussed with a healthcare provider.
  • Liver Function: Patients with liver problems may need dose adjustments.

Always inform your healthcare provider about all medications you’re taking and any medical conditions you have before starting Ondansetron.

Aspect Details
Study Types Bioequivalence studies, pharmacokinetic studies, safety and tolerability studies
Formulations Studied Tablets, Orally Disintegrating Tablets (ODT), Orally Dissolving Film Strips (ODFS)
Dosages 8 mg, 16 mg, 24 mg
Conditions Fasting and fed states
Main Outcomes Measured Area Under Curve (AUC), Maximum Plasma Concentration (Cmax), Time to Maximum Concentration (Tmax)
Study Designs Randomized, crossover, open-label
Comparisons Generic formulations vs. brand-name Zofran
Administration Routes Oral, subcutaneous, intramuscular, intravenous
Safety Assessments Adverse events, tolerability, infusion site observations

FAQ

  • What is Ondansetron used for? Ondansetron is primarily used to prevent nausea and vomiting, particularly in cases of postoperative recovery and chemotherapy-induced nausea and vomiting.
  • What different forms of Ondansetron were studied in these clinical trials? The trials studied various forms of Ondansetron, including regular tablets, orally disintegrating tablets (ODT), and orally dissolving film strips (ODFS).
  • What is bioequivalence, and why is it important in these studies? Bioequivalence refers to the comparison of different drug formulations to determine if they have the same effect in the body. It's important because it helps ensure that generic versions of a drug work as effectively as the brand-name version.
  • Were there any significant differences between fasting and fed conditions in the trials? Some trials specifically compared the bioequivalence of Ondansetron under fasting and fed conditions. This helps understand how food might affect the drug's absorption and effectiveness.
  • What were the main outcomes measured in these clinical trials? The main outcomes measured included the area under the plasma concentration-time curve (AUC), maximum plasma concentration (Cmax), time to reach maximum concentration (Tmax), and overall safety and tolerability of the drug.

Ongoing Clinical Trials on Ondansetron

  • Study Comparing 177Lu-PSMA-I&T with Apalutamide, Enzalutamide, and Abiraterone for Patients with Metastatic Hormone-Sensitive Prostate Cancer

    Recruiting

    1 1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study of palonosetron and fosaprepitant to prevent nausea and vomiting after laparoscopic surgery

    Not yet recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Sweden

  • Study on Switching from Dulaglutide to Tirzepatide for Adults with Type 2 Diabetes

    Not yet recruiting

    1 1 1 1
    Investigated drugs:
    Belgium France Germany Romania

  • Study on Reducing Body Temperature in Healthy Volunteers Using Pethidine and Buspirone to Prevent Shivering

    Not recruiting

    1 1
    Investigated drugs:
    Norway

  • Study on Amisulpride, Dexamethasone Phosphate, and Ondansetron for Preventing Post-Operative Nausea and Vomiting in Children

    Not recruiting

    1 1 1 1
    Investigated drugs:
    France Germany

  • Study for Adults with Very High-Risk T-Cell Acute Lymphoblastic Leukemia Using Daratumumab and a Drug Combination

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy

  • Study of Rituximab, Gemcitabine, Dexamethasone, and Platinum with or without Selinexor for Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not recruiting

    1 1 1
    Investigated drugs:
    Italy Poland Spain

  • Study of Azenosertib (ZN-c3) for Women with Recurrent or Persistent Uterine Serous Carcinoma

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    France Italy Spain

  • Study on the Safety and Effects of AZD9550 for Overweight and Obese Patients with Non-Alcoholic Steatohepatitis (NASH) with or without Type 2 Diabetes

    Not recruiting

    1 1
    Investigated diseases:
    Investigated drugs:
    Austria Germany Sweden

  • Study on the Effectiveness and Safety of Selinexor and Ruxolitinib for Patients with Myelofibrosis Who Have Not Received Prior Treatment

    Not recruiting

    1 1 1
    Investigated diseases:
    Investigated drugs:
    Belgium Bulgaria Czechia Denmark France Germany +7

Glossary

  • Bioequivalence: A comparison of different drug formulations to determine if they have the same effect in the body. It's used to ensure that generic versions of a drug work as effectively as the brand-name version.
  • Area Under Curve (AUC): A measure of the total exposure to a drug over time, used to assess how much and how long a drug is present in the body.
  • Orally Disintegrating Tablet (ODT): A tablet designed to dissolve quickly in the mouth without the need for water, making it easier to take for some patients.
  • Orally Dissolving Film Strip (ODFS): A thin, flexible strip that dissolves when placed on the tongue, delivering the medication without the need for water.
  • Fasting Condition: A state where the patient has not eaten for a certain period before taking the medication, typically used to study how the drug is absorbed without food interference.
  • Fed Condition: A state where the patient has eaten before taking the medication, used to study how food affects the drug's absorption and effectiveness.
  • Crossover Study: A type of clinical trial where participants receive different treatments in a specific order, allowing each person to serve as their own control.
  • Pharmacokinetics (PK): The study of how a drug moves through the body, including its absorption, distribution, metabolism, and excretion.
  • Maximum Plasma Concentration (Cmax): The highest concentration of a drug in the blood after it's been administered, used to assess how much of the drug is available in the body.
  • Time to Maximum Concentration (Tmax): The time it takes for a drug to reach its highest concentration in the blood after being administered.

References

  1. https://clinicaltrials.gov/study/NCT02386059
  2. https://clinicaltrials.gov/study/NCT01511705
  3. https://clinicaltrials.gov/study/NCT01679093
  4. https://clinicaltrials.gov/study/NCT01217190
  5. https://clinicaltrials.gov/study/NCT04703088